Pulmonary Fibrosis News and Research RSS Feed - Pulmonary Fibrosis News and Research

Combined risk score enhances radiation pneumonitis prediction

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows. [More]
FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). [More]
Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers. [More]
Gene variants that lead to longer telomeres boost brain cancer risk

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. [More]
Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014. [More]
Patient registry to help clinicians identify, manage people who have progressive lung disease

Patient registry to help clinicians identify, manage people who have progressive lung disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis. [More]
Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. [More]
Researchers find link between aging and chemicals in environment

Researchers find link between aging and chemicals in environment

Why are some 75-year-olds downright spry while others can barely get around? Part of the explanation, say researchers writing in the Cell Press journal Trends in Molecular Medicine on May 28, is differences from one person to the next in exposure to harmful substances in the environment, chemicals such as benzene, cigarette smoke, and even stress. [More]
X-ray dark-field radiography creates higher resolution images of lung disease

X-ray dark-field radiography creates higher resolution images of lung disease

Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease. [More]
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD). [More]
Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration. [More]
First Edition: May 19, 2014

First Edition: May 19, 2014

Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges. [More]

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). [More]

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States. [More]

PFF Patient Communication Center: The destination for latest disease education information

The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone. [More]
Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting. [More]
Protein molecule seems to slow progression of deadly lung disease

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis. [More]

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 - 21 May in San Diego [More]